Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) FCF Margin: 2012-2025

Historic FCF Margin for Agios Pharmaceuticals (AGIO) over the last 12 years, with Sep 2025 value amounting to -696.48%.

  • Agios Pharmaceuticals' FCF Margin rose 24771.00% to -696.48% in Q3 2025 from the same period last year, while for Sep 2025 it was -924.50%, marking a year-over-year increase of 7977.00%. This contributed to the annual value of -1,072.73% for FY2024, which is 3475.00% up from last year.
  • According to the latest figures from Q3 2025, Agios Pharmaceuticals' FCF Margin is -696.48%, which was down 11.21% from -626.25% recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' FCF Margin registered a high of -626.25% during Q2 2025, and its lowest value of -12,084.01% during Q1 2022.
  • For the 3-year period, Agios Pharmaceuticals' FCF Margin averaged around -1,039.05%, with its median value being -994.41% (2023).
  • Its FCF Margin has fluctuated over the past 5 years, first skyrocketed by 1,037,993bps in 2023, then slumped by 22,626bps in 2024.
  • Agios Pharmaceuticals' FCF Margin (Quarterly) stood at -1,537.73% in 2022, then soared by 51,391bps to -1,023.82% in 2023, then crashed by 22,626bps to -1,250.08% in 2024, then spiked by 24,771bps to -696.48% in 2025.
  • Its FCF Margin was -696.48% in Q3 2025, compared to -626.25% in Q2 2025 and -1,286.44% in Q1 2025.